Recent blog posts
Visible Lesion Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
Latest Hotspot
12 min read
Visible Lesion Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
24 August 2026
Evaluate Visible Lesion with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap MCP..
Read →
Tuberculosis, extrapulmonary Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
Latest Hotspot
12 min read
Tuberculosis, extrapulmonary Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
24 August 2026
Evaluate Tuberculosis, extrapulmonary in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap.
Read →
Congenital Structural Myopathy Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
Latest Hotspot
12 min read
Congenital Structural Myopathy Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
24 August 2026
Evaluate Congenital Structural Myopathy in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap.
Read →
Neuroendocrine neoplasm of lung Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
Latest Hotspot
12 min read
Neuroendocrine neoplasm of lung Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
24 August 2026
Evaluate Neuroendocrine neoplasm of in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap.
Read →
Clear Cell Sarcoma of Kidney Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
Latest Hotspot
12 min read
Clear Cell Sarcoma of Kidney Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
24 August 2026
Evaluate Clear Cell Sarcoma of Kidney in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap.
Read →
Brittle Bone Disorder Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
Latest Hotspot
12 min read
Brittle Bone Disorder Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
24 August 2026
Evaluate Brittle Bone Disorder with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap.
Read →
Biliary Tract Neoplasms Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
Latest Hotspot
12 min read
Biliary Tract Neoplasms Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
24 August 2026
Evaluate Biliary Tract Neoplasms in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Read →
Complement Component 3 Deficiency, Autosomal Recessive Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
Latest Hotspot
12 min read
Complement Component 3 Deficiency, Autosomal Recessive Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
24 August 2026
Evaluate Complement Component 3 in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Read →
Neuroendocrine Tumors Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
Latest Hotspot
12 min read
Neuroendocrine Tumors Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
24 August 2026
Evaluate Neuroendocrine Tumors with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap.
Read →
Anemia, Iron-Deficiency Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
Latest Hotspot
12 min read
Anemia, Iron-Deficiency Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
24 August 2026
Evaluate Anemia, Iron-Deficiency in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Read →
Epidermolysis Bullosa, Junctional Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
Latest Hotspot
12 min read
Epidermolysis Bullosa, Junctional Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
24 August 2026
Evaluate Epidermolysis Bullosa in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Read →
Angiomyolipoma Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
Latest Hotspot
12 min read
Angiomyolipoma Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
24 August 2026
Evaluate Angiomyolipoma with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap MCP..
Read →